- Home
- MCRB vs OPAL Comparison
MCRB vs OPAL Comparison
Compare MCRB & OPAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- OPAL
- Stock Information
- Founded
- MCRB 2010
- OPAL 1998
- Country
- MCRB United States
- OPAL United States
- Employees
- MCRB N/A
- OPAL N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- OPAL Natural Gas Distribution
- Sector
- MCRB Health Care
- OPAL Utilities
- Exchange
- MCRB Nasdaq
- OPAL Nasdaq
- Market Cap
- MCRB 131.0M
- OPAL 109.4M
- IPO Year
- MCRB 2015
- OPAL N/A
- Fundamental
- Price
- MCRB $0.73
- OPAL $3.26
- Analyst Decision
- MCRB Buy
- OPAL Buy
- Analyst Count
- MCRB 4
- OPAL 6
- Target Price
- MCRB $5.63
- OPAL $7.90
- AVG Volume (30 Days)
- MCRB 2.0M
- OPAL 130.7K
- Earning Date
- MCRB 03-04-2025
- OPAL 03-12-2025
- Dividend Yield
- MCRB N/A
- OPAL N/A
- EPS Growth
- MCRB N/A
- OPAL N/A
- EPS
- MCRB N/A
- OPAL 0.18
- Revenue
- MCRB $126,325,000.00
- OPAL $306,957,000.00
- Revenue This Year
- MCRB N/A
- OPAL $24.97
- Revenue Next Year
- MCRB N/A
- OPAL $32.05
- P/E Ratio
- MCRB N/A
- OPAL $18.55
- Revenue Growth
- MCRB 12856.41
- OPAL 30.17
- 52 Week Low
- MCRB $0.54
- OPAL $2.96
- 52 Week High
- MCRB $1.53
- OPAL $5.18
- Technical
- Relative Strength Index (RSI)
- MCRB 37.88
- OPAL 45.83
- Support Level
- MCRB $0.71
- OPAL $3.13
- Resistance Level
- MCRB $0.91
- OPAL $3.32
- Average True Range (ATR)
- MCRB 0.06
- OPAL 0.14
- MACD
- MCRB -0.02
- OPAL 0.00
- Stochastic Oscillator
- MCRB 8.37
- OPAL 31.71
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About OPAL OPAL Fuels Inc.
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.